Routine identification of fungal pathogens from positive blood cultures by culture-based methods can be time-consuming, delaying treatment with appropriate antifungal agents. The GenMark Dx ePlex investigational use only blood culture identification fungal pathogen panel (BCID-FP) rapidly detects 15 fungal targets simultaneously in blood culture samples positive for fungi by Gram staining. We aimed to determine the performance of the BCID-FP in a multicenter clinical study. Blood culture samples collected at 10 United States sites and tested with BCID-FP at 4 sites were compared to the standard-of-care microbiological and biochemical techniques, fluorescence in situ hybridization using peptide nucleic acid probes (PNA-FISH) and matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS). Discrepant results were analyzed by bi-directional PCR/sequencing of residual blood culture samples. A total of 866 clinical samples, 120 retrospectively and 21 prospectively collected, along with 725 contrived samples were evaluated. Sensitivity and specificity of detection of Candida species (C. albicans, C. auris, C. dubliniensis, C. famata, C. glabrata, C. guilliermondii, C. kefyr, C. krusei, C. lusitaniae, C. parapsilosis, and C. tropicalis) ranged from 97.1 to 100% and 99.8 to 100%, respectively. For the other organism targets, sensitivity and specificity were as follows: 100% each for Cryptococcus neoformans and C. gattii, 98.6% and 100% for Fusarium spp., and 96.2% and 99.9% for Rhodotorula spp., respectively. In 4 of the 141 clinical samples, the BCID-FP panel correctly identified an additional Candida species, undetected by standard-of-care methods. The BCID-FP panel offers a faster turnaround time for identification of fungal pathogens in positive blood cultures that may allow for earlier antifungal interventions and includes C. auris, a highly multidrug-resistant fungus.

Limited treatment options contribute to high morbidity/mortality rates with carbapenem-resistant, Gram-negative bacterial infections. New approaches for carbapenemase-producing organism (CPO) detection may help inform clinician decision-making on patient treatment and infection control. BD Phoenix CPO detect (CPO detect) detects and classifies carbapenemases in Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa during susceptibility testing. The clinical performance of CPO detect is reported here. Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa isolates were evaluated across three sites using CPO detect and a composite reference method (RM); the latter was comprised of the modified carbapenem inactivation method and a MIC screen for ertapenem, imipenem, and meropenem. Multiplex PCR testing was also utilized for Ambler class determination. Positive and negative percentages of agreement (PPA and NPA, respectively) between CPO detect and the RM were determined. The PPA and NPA for Enterobacterales were 98.5% (confidence intervals, 96.6%, 99.4%) and 97.2% (95.8%, 98.2%), respectively. The A. baumannii PPA and NPA, respectively, were 97.1% (90.2%, 99.2%) and 97.1% (89.9%, 99.2%). The P. aeruginosa PPA and NPA, respectively, were 95.9% (88.6%, 98.6%) and 92.3% (86.7%, 95.6%). The PPA values for carbapenemase class designations for all organisms combined and Enterobacterales alone, respectively, were 95.3% (90.2%, 97.8%) and 94.6% (88.8%, 97.5%) for class A, 94.0% (88.7%, 96.6%) and 96.4% (90.0%, 98.8%) for class B, and 95.0% (90.1%, 97.6%) and 99.0% (94.4%, 99.8%) for class D carbapenemases. NPA values for all organisms and Enterobacterales alone ranged from 98.5% to 100%. CPO detect provided accurate detection and classification of CPOs for the majority of isolates of Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa tested.

The QIAstat-Dx Respiratory Panel (QIAstat-Dx RP) is a multiplex in vitro diagnostic test for the qualitative detection of 20 pathogens directly from nasopharyngeal swab (NPS) specimens. The assay is performed using a simple sample-to-answer platform with results available in approximately 69 min. The pathogens identified are adenovirus, coronavirus 229E, coronavirus HKU1, coronavirus NL63, coronavirus OC43, human metapneumovirus A and B, influenza A, influenza A H1, influenza A H3, influenza A H1N1/2009, influenza B, parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, rhinovirus/enterovirus, respiratory syncytial virus A and B, Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. This multicenter evaluation provides data obtained from 1,994 prospectively collected and 310 retrospectively collected (archived) NPS specimens with performance compared to that of the BioFire FilmArray Respiratory Panel, version 1.7. The overall percent agreement between QIAstat-Dx RP and the comparator testing was 99.5%. In the prospective cohort, the QIAstat-Dx RP demonstrated a positive percent agreement of 94.0% or greater for the detection of all but four analytes: coronaviruses 229E, NL63, and OC43 and rhinovirus/enterovirus. The test also demonstrated a negative percent agreement of ≥97.9% for all analytes. The QIAstat-Dx RP is a robust and accurate assay for rapid, comprehensive testing for respiratory pathogens.

Cytogenetic risk stratification at diagnosis has long been one of the most useful tools to assess prognosis in acute lymphoblastic leukemia (ALL). To examine the prognostic impact of cytogenetic abnormalities on outcomes after allogeneic hematopoietic cell transplantation, we studied 1731 adults with Philadelphia-negative ALL in complete remission who underwent myeloablative or reduced intensity/non-myeloablative conditioning transplant from unrelated or matched sibling donors reported to the Center for International Blood and Marrow Transplant Research. A total of 632 patients had abnormal conventional metaphase cytogenetics. The leukemia-free survival and overall survival rates at 5 years after transplantation in patients with abnormal cytogenetics were 40% and 42%, respectively, which were similar to those in patients with a normal karyotype. Of the previously established cytogenetic risk classifications, modified Medical Research Council-Eastern Cooperative Oncology Group score was the only independent prognosticator of leukemia-free survival (P=0.03). In the multivariable analysis, monosomy 7 predicted post-transplant relapse [hazard ratio (HR)=2.11; 95% confidence interval (95% CI): 1.04-4.27] and treatment failure (HR=1.97; 95% CI: 1.20-3.24). Complex karyotype was prognostic for relapse (HR=1.69; 95% CI: 1.06-2.69), whereas t(8;14) predicted treatment failure (HR=2.85; 95% CI: 1.35-6.02) and overall mortality (HR=3.03; 95% CI: 1.44-6.41). This large study suggested a novel transplant-specific cytogenetic scheme with adverse [monosomy 7, complex karyotype, del(7q), t(8;14), t(11;19), del(11q), tetraploidy/near triploidy], intermediate (normal karyotype and all other abnormalities), and favorable (high hyperdiploidy) risks to prognosticate leukemia-free survival (P=0.02). Although some previously established high-risk Philadelphia-negative cytogenetic abnormalities in ALL can be overcome by transplantation, monosomy 7, complex karyotype, and t(8;14) continue to pose significant risks and yield inferior outcomes.

PURPOSE

We aimed to evaluate the efficacy and safety of use of the Fasting Algorithm for Singaporeans with Type 2 Diabetes (FAST) during Ramadan.

METHODS

We performed a prospective, multicenter, randomized controlled trial. The inclusion criteria were age ≥21 years, baseline glycated hemoglobin (HbA_1c) level ≤9.5%, and intention to fast for ≥10 days during Ramadan. Exclusion criteria included baseline estimated glomerular filtration rate <30 mL/min, diabetes-related hospitalization, and short-term corticosteroid therapy. Participants were randomized to intervention (use of FAST) or control (usual care without FAST) groups. Efficacy outcomes were HbA_1c level and fasting blood glucose and postprandial glucose changes, and the safety outcome was incidence of major or minor hypoglycemia during the Ramadan period. Glycemic variability and diabetes distress were also investigated. Linear mixed models were constructed to assess changes.

RESULTS

A total of 97 participants were randomized (intervention: n = 46, control: n = 51). The HbA_1c improvement during Ramadan was 4 times greater in the intervention group (–0.4%) than in the control group (–0.1%) (P = .049). The mean fasting blood glucose level decreased in the intervention group (–3.6 mg/dL) and increased in the control group (+20.9 mg/dL) (P = .034). The mean postprandial glucose level showed greater improvement in the intervention group (–16.4 mg/dL) compared to the control group (–2.3 mg/dL). There were more minor hypoglycemic events based on self-monitered blood glucose readings in the control group (intervention: 4, control: 6; P = .744). Glycemic variability was not significantly different between the 2 groups (P = .284). No between-group differences in diabetes distress were observed (P = .479).

CONCLUSIONS

Our findings emphasize the importance of efficacious, safe, and culturally tailored epistemic tools for diabetes management.

S100A8/A9 is implicated in inflammation mechanisms related to atherosclerosis and plaque vulnerability, but it remains unclear whether S100A8/A9 is associated with the prognosis of ischemic stroke. The aim of this study was to investigate these associations in 2 independent multicenter cohorts.Plasma S100A8/A9 concentrations at baseline were measured among 4785 patients with ischemic stroke from 2 independent cohorts: Infectious Factors, Inflammatory Markers, and Prognosis of Acute Ischemic Stroke (IIPAIS) and China Antihypertensive Trial in Acute Ischemic Stroke (CATIS). The primary outcome was a composite outcome of death or major disability at 3 months after ischemic stroke. Secondary outcomes were major disability, death, and a composite outcome of death or vascular events.Among the combined participants of IIPAIS and CATIS, the adjusted odds ratios associated with the highest quartile of plasma S100A8/A9 were 2.11 (95% CI, 1.66–2.68) for the primary outcome and 1.62 (95% CI, 1.27–2.07) for the secondary outcome of major disability; adjusted hazard ratios were 4.14 (95% CI, 2.10–8.15) for the secondary outcome of death and 2.08 (95% CI, 1.38–3.13) for the composite outcome of death or vascular events. Each SD increase of log-transformed S100A8/A9 was associated with 28% (95% CI, 18%–39%; P < 0.001) increased risk of the primary outcome. Multivariable-adjusted spline regression analyses showed a linear association between plasma S100A8/A9 concentrations and primary outcome (P < 0.001 for linearity). Subgroup analyses further confirmed these associations.High plasma S100A8/A9 concentrations at baseline were independently associated with increased risks of adverse clinical outcomes at 3 months after ischemic stroke, suggesting that S100A8/A9 might have a role as a prognostic marker of ischemic stroke.

Purpose:

Preclinical data demonstrating androgen receptor (AR)–positive (AR⁺) triple-negative breast cancer (TNBC) cells are sensitive to AR antagonists, and PI3K inhibition catalyzed an investigator-initiated, multi-institutional phase Ib/II study TBCRC032. The trial investigated the safety and efficacy of the AR-antagonist enzalutamide alone or in combination with the PI3K inhibitor taselisib in patients with metastatic AR⁺ (≥10%) breast cancer.

Patients and Methods:

Phase Ib patients [estrogen receptor positive (ER⁺) or TNBC] with AR⁺ breast cancer received 160 mg enzalutamide in combination with taselisib to determine dose-limiting toxicities and the maximum tolerated dose (MTD). Phase II TNBC patients were randomized to receive either enzalutamide alone or in combination with 4 mg taselisib until disease progression. Primary endpoint was clinical benefit rate (CBR) at 16 weeks.

Results:

The combination was tolerated, and the MTD was not reached. The adverse events were hyperglycemia and skin rash. Overall, CBR for evaluable patients receiving the combination was 35.7%, and median progression-free survival (PFS) was 3.4 months. Luminal AR (LAR) TNBC subtype patients trended toward better response compared with non-LAR (75.0% vs. 12.5%, P = 0.06), and increased PFS (4.6 vs. 2.0 months, P = 0.082). Genomic analyses revealed subtype-specific treatment response, and novel FGFR2 fusions and AR splice variants.

Conclusions:

The combination of enzalutamide and taselisib increased CBR in TNBC patients with AR⁺ tumors. Correlative analyses suggest AR protein expression alone is insufficient for identifying patients with AR-dependent tumors and knowledge of tumor LAR subtype and AR splice variants may identify patients more or less likely to benefit from AR antagonists.

Although they are usually not considered to be diabetes complications, musculoskeletal disorders (MSKDs) are common in individuals with type 1 or type 2 diabetes and can strongly interfere with daily diabetes care, especially in people using diabetes technologies. The authors of this retrospective study in a population of 140 patients with type 1 diabetes report the distribution of subtypes of MSKDs and speculate about the mechanisms involved. The authors emphasize the need for multidisciplinary care involving not only the diabetes care team but also orthopedic surgeons. This report should lead to large, prospective studies to increase knowledge about these under-studied complications.

Background:

The success of multisite collaborative research relies on effective data collection, harmonization, and aggregation strategies. Data Coordination Centers (DCC) serve to facilitate the implementation of these strategies. The utility of a DCC can be particularly relevant for research on rare diseases where collaboration from multiple sites to amass large aggregate datasets is essential. However, approaches to building a DCC have been scarcely documented.

Methods:

The Li-Fraumeni Exploration (LiFE) Consortium's DCC was created using multiple open source packages, including LAM/G Application (Linux, Apache, MySQL, Grails), Extraction-Transformation-Loading (ETL) Pentaho Data Integration Tool, and the Saiku-Mondrian client. This document serves as a resource for building a rare disease DCC for multi-institutional collaborative research.

Results:

The primary scientific and technological objective to create an online central repository into which data from all participating sites could be deposited, harmonized, aggregated, disseminated, and analyzed was completed. The cohort now include 2,193 participants from six contributing sites, including 1,354 individuals from families with a pathogenic or likely variant in TP53. Data on cancer diagnoses are also available. Challenges and lessons learned are summarized.

Conclusions:

The methods leveraged mitigate challenges associated with successfully developing a DCC's technical infrastructure, data harmonization efforts, communications, and software development and applications.

Impact:

These methods can serve as a framework in establishing other collaborative research efforts. Data from the consortium will serve as a great resource for collaborative research to improve knowledge on, and the ability to care for, individuals and families with Li-Fraumeni syndrome.

Chiết khấu cực khủng 30 - 40% từ cđt hưng thịnh, mua căn 1.9 tỷ giảm còn 1.1 tỷ.Sở hữu vị trí vàng 01 Nguyễn Tất Thành Thành phố Quy Nhơn với 4 mặt tiền đường, 3 mặt view biển và 1 mặt view hồ Bầu Sen, CDT Hưng Thịnh trân trọng gửi tới quý KH dự án căn hộ Smarthome đầu tiên tại t...

1. Giới thiệu tư vấn các loại hình bất động sản
2. Tư vấn, hỗ trợ pháp lý liên quan đến BDS, trung tâm thành phố và ven đô
3. Nhận, ký gửi, mua bán tất cả các loại bất động sản trên thị trường TP. Hồ Chí Minh

Slogan: Đối tác trung gian tin cậy - Tư vấn đầu từ hiệu quả 

Sau thời gian hình thành và phát triển, dù trải qua nhiều thử thách nhưng với chiến lược phù hợp cùng tư duy quản trị đúng đắn và tinh thần đoàn kết, nỗ lực của toàn công ty, thương hiệu Saigon Center Real ngày càng được khẳng định một cách vững chắc trên thị trường, được khách hàng xem là một Công ty tư vấn đầu tư uy tín số 1 trong ngành dịch vụ Bất động sản Việt Nam.

Nhờ sự đồng lòng, tinh thần đoàn kết và trách nhiệm cao của toàn tập thể công ty cùng sự tín nhiệm, ủng hộ của khách hàng trong suốt thời gian qua, Saigon Center Real đang dần hoàn thiện và phát triển mình.

Đội ngũ SGCR có thu nhập cực cao, trong đó các super sale có doanh số năm 2018 và 2019 là 12 tỷ. Chúng tôi tự hào là tổ chức phát triển nhà lãnh đạo và phát triển các chuyên gia bán hàng xuất sắc nhất Việt Nam, nơi hội tụ nhiều cá nhân tài năng, những người nhân cách lớn và giàu khát vọng, những người luôn sục sôi chí lớn, ngày đêm rèn luyện tài năng, nghiền ngẫm, vận dụng và sáng tạo trong công việc. Luôn ý thức được sứ mệnh của mình như những “thiên sứ” mang lại tổ ấm cho những gia đình khách hàng để họ có thể an cư lạc nghiệp.

Gia nhập vào đại gia đình Saigon Center Real, bạn sẽ có những người bạn, người đồng nghiệp thân thiết gắn bó, chia sẻ những khó khăn trong công việc và cuộc sống. Toàn thể tập thể công ty Saigon Center Real luôn tràn đầy nhiệt huyết - khát vọng, ham học hỏi và không ngừng phấn đấu để vượt qua mọi thách thức, chinh phục mọi thành công.

Với mục tiêu và tầm nhìn tới năm 2025, Saigon Center Real sẽ có mặt tại 63 tỉnh thành trên cả nước với qui mô nhân sự khoảng 10.000 người & trở thành công ty dịch vụ BĐS lớn nhất Việt Nam.

Chúng tôi sẽ làm nên " lịch sử" của ngành dịch vụ BĐS truyền thống Việt Nam & hướng tới mở văn phòng giao dịch tại các nước trên thế giới với qui mô nhân sự khoảng 30 ngàn người vào năm 2030 để trở thành nhà phân phối bất động sản số 1 thế giới, đóng góp vào sự phát triển của ngành bất động sản và nền kinh tế Việt Nam hoà nhập với nền kinh tế thế giới.

Đó là khát vọng, là lý tưởng là "sứ mệnh lịch sử'' của ban lãnh đạo và tất cả mọi thành viên công ty Saigon Center Real cùng nhau hướng tới cuộc sống: “Giàu có - Thành công và Hạnh phúc trọn vẹn”.

Hotline: 0909792352

Danh sách các chi nhánh của Công ty :

• Trụ sở Nguyễn Huệ, Quận 1.
• Chi nhánh Itaxa Quận 3.
• Chi nhánh An Dương Vương, Quận 5.
• Chi nhánh Nguyễn Văn Trỗi, Quận Phú Nhuận.
• Chi nhánh Trần Não, Quận 2.
• Chi nhánh Nguyễn Văn Đậu, Quận Gò Vấp.
• Chi Nhánh Ung Văn Khiêm, Quận Bình Thạnh.
• Chi nhánh Cộng Hòa, Quận Tân Bình.
• Chi Nhánh Quang Trung, Quận 12.
• Chi Nhánh Tô Hiến Thành, Quận 10.

Trân trọng cảm ơn!

QUY NHON GRAND CENTER PRIME LOCATION ARTERIAL ROAD, PRICE ONLY FROM 38 million VND/M2 Long-term apartment. Location: + 1 Nguyen Tat Thanh street, Ly Thuong Kiet ward, Quy Nhon city. + Owns four frontage roads: Nguyen Tat Thanh, Ly Thuong Kiet, Ton Duc Thang, and Mai Xuan Thuong. ...

Khu dân cư ĐTP Eco Center được phát triển trên quỹ đất rộng 2.3ha với quy mô gồm 100 sản phẩm đất nền có diện tích đa dạng.

Thạnh Phú Center là dự án đất nền do chủ đầu tư Úc Thắng triển khai trên quỹ đất rộng 11.7ha tại thị trấn Thạnh Phú, huyện Thạnh Phú, tỉnh Bến Tre.

Vincom Center Long Bien nằm ở vị trí trung tâm trong dự án Vincom Village, dự án được tạo nên bởi hệ thống phân khu chức năng riêng biệt: khu mua sắm, khu vui chơi, khu ẩm thực, siêu thị tiêu dùng…

Vincom Center Phạm Ngọc Thạch là một trong những dự án của Tập đoàn Vingroup, dứ án hứa hẹn sẽ đem đến một quần thể đẳng cấp với những tiện ích vượt trội.

Recently, TTC Land has officially launched the first service office line at Jamona Heights apartment in District 7, office apartments designed according to Korean standards designed by GanSam Corporation (Korean). , with a prime location in the heart of South Saigon. Project loca...

Area: Apartment for sale in Jamona Heights - District 7 - Ho Chi MinhPrice: 1.3 billion Area: 30mDescriptive InformationSmart investment opportunities- Buy 1 get 2 with TTC Land's Smartel Jamona Heights.- While doing company offices - just living.- Diverse area of 30m2 - 79m2.- O...

PROPERTY DETAILS: - 2BRs on 24th floor - Facing to Saigon river & Saigon Pearl villas - GFA: 106.62 sqm - Selling price: 8,9 billion VND - Estimated rental income: $1,500 monthly ***Rental yields is around 6,7% per year.DEVELOPER: Sunwah Group is a highly diversified conglomerat...

DEVELOPER: Sunwah Group is a highly diversified conglomerate with businesses in seven principal areas: Seafood & Foodstuff, Real Estate, Financial Services, Technology, Media, Infrastructure and Education and training. Activities extend deep into Mainland China as well as to the ...

1 Bedroom Apartment for sale at The Marq - new masterpiece in Hochiminh City center by Hongkong LandHongkong Land announced the launch of The Marq, which will be opened for sale in the first half of 2019. Located in the heart of District 1, the development will provide 515 opulen...

Townhouse For Rent In The Center Of Saigon- Vo Van Tan Street- District 3 - Location: is the intersection of Cao Thang Street, busy business - Area : 5m * 18m - Structure : 4 to 5 floors, including 9 rooms - The rental price : $4500/Month (excluding VAT) equivalent to VND 103,500...

Area: Apartment for sale in Jamona Heights - District 7 - Ho Chi MinhPrice: 1.3 billion Area: 30mDescriptive InformationSmart investment opportunities- Buy 1 get 2 with TTC Land's Smartel Jamona Heights.- While doing company offices - just living.- Diverse area of 30m2 - 79m2.- O...

Recently, TTC Land has officially launched the first service office line at Jamona Heights apartment in District 7, office apartments designed according to Korean standards designed by GanSam Corporation (Korean). , with a prime location in the heart of South Saigon.Hotline: 0398...

Chiết khấu cực khủng đến 40% - Sở hữu ngay căn hộ giá rẻ không tưởng chỉ còn 1.1 tỷ - Dự án pháp lý vững chắc - Sở hữu lâu dài - Vị trí vàng 4 mặt tiền đường trung tâm TP Quy Nhơn - Đầy đủ mọi tiện ích hồ bơi tràn, công viên ánh sáng, trung tâm mua sắm - Ngắm nhìn toàn cảnh phố b...

Khu đô thị Lạc Vệ New Center được triển khai trên quỹ đất rộng 5.5ha với mật độ xây dựng khoảng 44.5% - hướng đến xây dựng một đô thị theo mô hình xanh - sạch - đẹp để phục vụ cư dân tại xã Lạc Vệ, huyện Tiên Du, tỉnh Bắc Ninh.

The overlooked epicenter of the Covid-19 pandemic is our nation's nursing homes, veterans' homes, and other long-term care facilities.

Host Aziz Ansari touched upon the Women's Marches, racism and immigration in his monologue.

Andrea Arroyo

The post The Pandemic’s Impact on Immigration Detention Centers appeared first on The Nation.

While Americans are sheltering in place, the federal government is shuffling hundreds of immigrant detainees between U.S. towns, putting vulnerable communities at risk.

Regency Nursing and Rehabilitation Centers Inc. nursing home chain will pay the United States $4 million to settle allegations that Regency submitted false claims to Medicare and the Texas Medicaid program. The Victoria, Texas-based chain currently owns and operates 24 nursing home facilities located through the state.

The United States has joined a whistleblower suit against Science Applications International Corp. (SAIC); Applied Enterprise Solutions (AES); Dale Galloway, Chief Executive Officer of AES; Stephen Adamec, former Director of the Naval Oceanographic Major Shared Resource Center (NAVO MSRC) at the Stennis Space Center in Hancock County, Mississippi; and Robert Knesel, Deputy Director of NAVO MSRC.

Deputy Attorney General David W. Ogden today announced plans by the Department of Justice to significantly expand its training and education operations at the National Advocacy Center (NAC), the core training facility for local, state and federal attorneys, law enforcement agents and support personnel.

"The Palmetto Project – as it is known – will allow the Department of Justice to expand the capabilities of the National Advocacy Center. As the core training center for prosecutors, law enforcement agents and other personnel from across the nation, the NAC is crucial to the continued success of the Justice Department’s mission."

Covenant Medical Center in Waterloo, Iowa has agreed to pay the United States $4.5 million to resolve allegations that it violated the False Claims Act. This settlement resolves allegations that Covenant submitted false claims to Medicare by having financial relationships with five physicians that violated the Stark Law.

"The work we have begun in the administration has already made a difference. What we are looking for are the short- and long-term solutions that combine the lessons learned from the past with the resources have, and will continue to fight for, in the future."

Eric Ian Baker pleaded guilty today in federal court in Nashville, Tenn., for his role in burning and vandalizing the Islamic Center of Columbia, Tenn., on Feb. 9, 2008. Baker was charged with violating civil rights that protect religious property and for using fire in the commission of a felony.

Pine Hills Kiddie Garden of Fort Wayne, Ind., will take necessary steps to ensure that a child’s diabetes care is integrated into the usual routine of its day care center and programs as part of a settlement to resolve allegations that it discriminated on the basis of disability.

The department today announced a comprehensive settlement agreement under the Americans with Disabilities Act (ADA) with the Beth Israel Deaconess Medical Center (BIDMC) in Brookline, Mass., to ensure access to medical facilities and services for individuals with disabilities.

"Let us ensure that we further Justice Brennan’s legacy by maintaining the most basic constitutional protection—the right to have truly effective defense counsel."

“The right to worship without fear of this kind of violent interference is among our most fundamental civil rights,” said Thomas E. Perez, Assistant Attorney General for the Civil Rights Division.

The Department’s Civil Rights Division and the U.S. Attorney’s Office for the Eastern District of New York have entered into an agreement with New York City to correct conditions of confinement at the Kings County Hospital Center’s (KCHC) psychiatric emergency room and psychiatric in-patient units located in Brooklyn, N.Y.

The United States has obtained a $10 million consent judgment against Los Angeles businessman Robert Bourseau and Dr. Rudra Sabaratnam for a Medicare and Medi-Cal fraud scheme arising from their former ownership of the Los Angeles City of Angels Medical Center.

"We need this Civil Rights Museum so that we remember our history, however painful it may be," said Assistant Attorney General Perez.

The Department announced a settlement agreement with The Children’s House Inc. of Broadview Heights, Ohio, a suburb of Cleveland, to provide services for children with asthma as required by the Americans with Disabilities Act (ADA).

"I’m proud of what’s been accomplished, in a very short time, by our fusion centers," said Attorney General Holder.

Brookhaven Memorial Hospital Medical Center, a Long Island, N.Y.-based hospital, has agreed to pay $2.92 million, plus interest, to settle allegations that the hospital defrauded Medicare.